Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...

Vine is a nostalgic reboot of Vine’s classic six-second loops with restored archives and human-made clips for short-form creators.

MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ:MDAI) reported third quarter earnings results on November 11 th . Highlights since our previous update include several presentations ...

While self-healing agentic test suites can help eliminate the manual intervention consuming engineering cycles, there are key ...

Artificial intelligence has redefined what it means to measure and understand human intelligence. Once limited to ...

By enhancing metabolism and oxygen consumption, the device can help burn more calories during and after each session, aiding ...